Table 5.
Summary of a number of large studies that reported associations between TERT promoter mutations and clinicopathological features of FTC or ATC
| FTC | ATC | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Muzza et al. 2015 [30] | Melo M et al. 2014 [36] | Wang N et al. 2014 [34] | Liu T et al. 2014 [37] | Shi X et al. 2015 [28] | |||||||||||
| Mutant (8) | Wild (50) | P value | Mutant (12) | Wild (58) | P value | Mutant (9) | Wild (42) | P value | Mutant (8) | Wild (28) | P value | Mutant (18) | Wild (28) | P value | |
| Age | 66 (48–81) | 56 (18–85) | 0.04 | 63.8 ± 11.0 | 49.3 ± 16.3 | 0.004 | 66 ± 16 | 54 ± 19 | 0.052 | 69 (31–83) | 54 (17–77) | 0.05 | 68.7 ± 12.5 | 60.4 ± 11.2 | 0.023 |
| Size | 5.4 | 4.09 | 0.1 | 4.4 ± 2.5 | 4.4 ± 2.6 | 0.96 | 5.0 (3.5–6.7) | 6.0 (3.5–7.5) | 0.46 | ||||||
| ETE | 5/8 (62.5 %) | 24/50 (48 %) | 0.7 | 3/8 (37.5 %) | 5/41 (12.2 %) | 0.08 | 18/18 (100 %) | 22/24 (91.6 %) | 0.49 | ||||||
| Vascular invasion | 8/10 (80 %) | 31/43 (72.1 %) | 0.61 | ||||||||||||
| LNM | 7/8 (87.5 %) | 46/50 (92 %) | 0.7 | 3/12 (25 %) | 5/35 (14.3 %) | 0.39 | 11/17 (64.7 %) | 13/21 (61.9 %) | 0.86 | ||||||
| Distant mets | 5/5 (100 %) | 3/26 (11.5 %) | 0.001 | 15/18 (83.3 %) | 8/26 (30.8 %) | 0.001 | |||||||||
| TNM III and IV | 6/8 (75 %) | 23/50 (46 %) | 0.02 | 5/6 (83.3 %) | 8/23 (34.8 %) | 0.007 | |||||||||
| Recurrence | 5/8 (62.5 %) | 11/50 (22 %) | 0.03 | ||||||||||||
| Death | 2/12 (16.7 %) | 0/58 (0) | <0.001 | ||||||||||||
ETE extrathyroidal extension/invasion, LNM lymph node metastases, Mets metastases, TNM tumor node metastasis staging system